Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.17
LCI's Cash-to-Debt is ranked lower than
86% of the 815 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.12 vs. LCI: 0.17 )
Ranked among companies with meaningful Cash-to-Debt only.
LCI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 1.78 Max: N/A
Current: 0.17
Equity-to-Asset 0.34
LCI's Equity-to-Asset is ranked lower than
84% of the 739 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. LCI: 0.34 )
Ranked among companies with meaningful Equity-to-Asset only.
LCI' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.17  Med: 0.71 Max: 0.92
Current: 0.34
-0.17
0.92
Interest Coverage 0.92
LCI's Interest Coverage is ranked lower than
95% of the 638 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 118.48 vs. LCI: 0.92 )
Ranked among companies with meaningful Interest Coverage only.
LCI' s Interest Coverage Range Over the Past 10 Years
Min: 0.92  Med: 47.21 Max: 1094.14
Current: 0.92
0.92
1094.14
Piotroski F-Score: 3
Altman Z-Score: 1.49
Beneish M-Score: -2.61
WACC vs ROIC
12.31%
15.52%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 13.28
LCI's Operating Margin % is ranked higher than
66% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. LCI: 13.28 )
Ranked among companies with meaningful Operating Margin % only.
LCI' s Operating Margin % Range Over the Past 10 Years
Min: -7.5  Med: 9.74 Max: 55.67
Current: 13.28
-7.5
55.67
Net Margin % -0.41
LCI's Net Margin % is ranked lower than
72% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.26 vs. LCI: -0.41 )
Ranked among companies with meaningful Net Margin % only.
LCI' s Net Margin % Range Over the Past 10 Years
Min: -8.39  Med: 5.87 Max: 36.85
Current: -0.41
-8.39
36.85
ROE % -0.50
LCI's ROE % is ranked lower than
70% of the 792 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. LCI: -0.50 )
Ranked among companies with meaningful ROE % only.
LCI' s ROE % Range Over the Past 10 Years
Min: -9.5  Med: 8.85 Max: 39.56
Current: -0.5
-9.5
39.56
ROA % -0.16
LCI's ROA % is ranked lower than
68% of the 821 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. LCI: -0.16 )
Ranked among companies with meaningful ROA % only.
LCI' s ROA % Range Over the Past 10 Years
Min: -6.58  Med: 4.71 Max: 35.21
Current: -0.16
-6.58
35.21
ROC (Joel Greenblatt) % 18.55
LCI's ROC (Joel Greenblatt) % is ranked higher than
59% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.07 vs. LCI: 18.55 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
LCI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -12.51  Med: 27.67 Max: 133.12
Current: 18.55
-12.51
133.12
3-Year Revenue Growth Rate 40.60
LCI's 3-Year Revenue Growth Rate is ranked higher than
95% of the 640 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. LCI: 40.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
LCI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -20.8  Med: 13.45 Max: 91.7
Current: 40.6
-20.8
91.7
3-Year EBITDA Growth Rate 66.40
LCI's 3-Year EBITDA Growth Rate is ranked higher than
94% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. LCI: 66.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
LCI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -92  Med: 46.05 Max: 153.4
Current: 66.4
-92
153.4
3-Year EPS without NRI Growth Rate 37.70
LCI's 3-Year EPS without NRI Growth Rate is ranked higher than
84% of the 580 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.90 vs. LCI: 37.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
LCI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -58.1  Med: 37.7 Max: 206.7
Current: 37.7
-58.1
206.7
GuruFocus has detected 4 Warning Signs with Lannett Co Inc $LCI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» LCI's 30-Y Financials

Financials (Next Earnings Date: 2017-08-02 Est.)



Strict Standards: Only variables should be passed by reference in /home/gurufocu/public_html/modules/stock/financials_highchart_morn.php on line 23
Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:DEPO, NAS:HRTX, OTCPK:LPCUF, NAS:AMPH, NAS:FLXN, OTCPK:TZHGF, NAS:INNL, OTCPK:APHQF, NAS:SCLN, OTCPK:ACBFF, NAS:SCMP, NAS:TLGT, OTCPK:CSWYF, OTCPK:TWMJF, NAS:KPTI, NAS:ACET, NAS:LBIO, NAS:SGYP, OTCPK:NPPNY, OTCPK:KHTRF » details
Traded in other countries:LN5.Germany,
Headquarter Location:USA
Lannett Co Inc develops, manufactures, packages, markets and distributes generic versions of branded pharmaceutical products. Its products include solid oral dosage forms, including oral solutions, nasal, topicals or parentarels.

Lannett Co Inc was incorporated in 1942 under the laws of the Commonwealth of Pennsylvania, and reincorporated in 1991 as a Delaware corporation. The Company develops, manufactures, markets and distributes generic versions of branded pharmaceutical products. The Company manufactures solid oral dosage forms, including tablets and capsules, extended release, topicals, oral solutions and distributes parenteral as well as ophthalmics. All of the products are currently manufactured and sold are prescription products. The Company's products containing Levo are produced and marketed with 12 varying potencies. In addition to generic Levo tablets, it also market and distribute Unithroid tablets, a branded version of Levo, which is produced and marketed with 11 varying potencies. Both generic Levo tablets and Unithroid tablets are manufactured by JSP. Lannett began buying generic Levo from JSP and selling it to its customers in April 2003. Levo tablets are used to treat hypothyroidism and other thyroid disorders. Levo remains the most prescribed drugs in the U.S. and is used by over 13 million patients of various ages and demographic backgrounds. In distribution of these products, the Company competes with two branded Levo products-Abbott Laboratories Synthroid(r) and Monarch Pharmaceuticals Levoxyl(r)- as well as generic products from Mylan and Sandoz. Digoxin tablets are produced and marketed with two different potencies, 0.125mg and 0.25mg per tablet. This product is manufactured by JSP. Lannett began buying this product from JSP and selling it to its customers in September 2002. Digoxin tablets are used to treat congestive heart failure in patients of various ages and demographic backgrounds. The Company distributes two products containing Butalbital. Lannett has manufactured and sold one of the products, Butalbital with Aspirin and Caffeine capsules, for more than nine years. The other Butalbital product, Butalbital with Aspirin, Caffeine and Codeine Phosphate capsules, is manufactured by JSP. Lannett began buying this product from JSP and selling it to its customers in December 2002. Both Butalbital products, which are in orally administered capsule dosage forms, are prescribed to treat tension headaches caused by contractions of the muscles in the neck and shoulder area and migraine. Primidone tablets are produced and marketed with two different potencies, 50mg and 250mg tablets. Lannett has developed and manufacture Primidone tablets and began selling Primidone 50mg tablets in June 2001. In addition, the Company has been manufacturing and selling Primidone 250mg tablets for more than seven years. Both Primidone products, which are in orally administered tablet dosage forms, are prescribed to treat convulsion and seizures in epileptic patients of all ages and demographic backgrounds. Lannett sell its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, ma

Ratios

vs
industry
vs
history
Forward PE Ratio 7.18
NYSE:LCI's Forward PE Ratio is ranked higher than
93% of the 68 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.46 vs. NYSE:LCI: 7.18 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 175.00
NYSE:LCI's Price-to-Owner-Earnings is ranked lower than
91% of the 304 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.00 vs. NYSE:LCI: 175.00 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
NYSE:LCI' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.44  Med: 19.3 Max: 834.91
Current: 175
4.44
834.91
PB Ratio 1.33
NYSE:LCI's PB Ratio is ranked higher than
81% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. NYSE:LCI: 1.33 )
Ranked among companies with meaningful PB Ratio only.
NYSE:LCI' s PB Ratio Range Over the Past 10 Years
Min: 0.61  Med: 1.65 Max: 6.39
Current: 1.33
0.61
6.39
PS Ratio 1.12
NYSE:LCI's PS Ratio is ranked higher than
81% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. NYSE:LCI: 1.12 )
Ranked among companies with meaningful PS Ratio only.
NYSE:LCI' s PS Ratio Range Over the Past 10 Years
Min: 0.48  Med: 1.41 Max: 7.1
Current: 1.12
0.48
7.1
Price-to-Free-Cash-Flow 8.04
NYSE:LCI's Price-to-Free-Cash-Flow is ranked higher than
89% of the 209 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.35 vs. NYSE:LCI: 8.04 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
NYSE:LCI' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.22  Med: 20.97 Max: 489.29
Current: 8.04
3.22
489.29
Price-to-Operating-Cash-Flow 5.63
NYSE:LCI's Price-to-Operating-Cash-Flow is ranked higher than
90% of the 281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.13 vs. NYSE:LCI: 5.63 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
NYSE:LCI' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 2.89  Med: 15.27 Max: 288.5
Current: 5.63
2.89
288.5
EV-to-EBIT 17.30
NYSE:LCI's EV-to-EBIT is ranked higher than
61% of the 563 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.48 vs. NYSE:LCI: 17.30 )
Ranked among companies with meaningful EV-to-EBIT only.
NYSE:LCI' s EV-to-EBIT Range Over the Past 10 Years
Min: -277  Med: 12.4 Max: 348.4
Current: 17.3
-277
348.4
EV-to-EBITDA 10.66
NYSE:LCI's EV-to-EBITDA is ranked higher than
76% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.55 vs. NYSE:LCI: 10.66 )
Ranked among companies with meaningful EV-to-EBITDA only.
NYSE:LCI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -2304.2  Med: 10.9 Max: 681
Current: 10.66
-2304.2
681
Shiller PE Ratio 25.49
NYSE:LCI's Shiller PE Ratio is ranked higher than
73% of the 197 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 38.91 vs. NYSE:LCI: 25.49 )
Ranked among companies with meaningful Shiller PE Ratio only.
NYSE:LCI' s Shiller PE Ratio Range Over the Past 10 Years
Min: 23.48  Med: 79.67 Max: 1389
Current: 25.49
23.48
1389
Current Ratio 2.63
NYSE:LCI's Current Ratio is ranked higher than
54% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. NYSE:LCI: 2.63 )
Ranked among companies with meaningful Current Ratio only.
NYSE:LCI' s Current Ratio Range Over the Past 10 Years
Min: 0.99  Med: 2.39 Max: 10.52
Current: 2.63
0.99
10.52
Quick Ratio 2.04
NYSE:LCI's Quick Ratio is ranked higher than
54% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. NYSE:LCI: 2.04 )
Ranked among companies with meaningful Quick Ratio only.
NYSE:LCI' s Quick Ratio Range Over the Past 10 Years
Min: 0.26  Med: 1.69 Max: 9.3
Current: 2.04
0.26
9.3
Days Inventory 131.34
NYSE:LCI's Days Inventory is ranked lower than
57% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.36 vs. NYSE:LCI: 131.34 )
Ranked among companies with meaningful Days Inventory only.
NYSE:LCI' s Days Inventory Range Over the Past 10 Years
Min: 68.82  Med: 107.64 Max: 165.34
Current: 131.34
68.82
165.34
Days Sales Outstanding 118.47
NYSE:LCI's Days Sales Outstanding is ranked lower than
76% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.70 vs. NYSE:LCI: 118.47 )
Ranked among companies with meaningful Days Sales Outstanding only.
NYSE:LCI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 78.9  Med: 98.94 Max: 171.98
Current: 118.47
78.9
171.98
Days Payable 52.24
NYSE:LCI's Days Payable is ranked lower than
66% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.86 vs. NYSE:LCI: 52.24 )
Ranked among companies with meaningful Days Payable only.
NYSE:LCI' s Days Payable Range Over the Past 10 Years
Min: 44.61  Med: 74.51 Max: 88.36
Current: 52.24
44.61
88.36

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.30
NYSE:LCI's 3-Year Average Share Buyback Ratio is ranked lower than
64% of the 477 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. NYSE:LCI: -8.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NYSE:LCI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -37  Med: -5.9 Max: 26.7
Current: -8.3
-37
26.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.59
NYSE:LCI's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
94% of the 329 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. NYSE:LCI: 0.59 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
NYSE:LCI' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.57  Med: 1.36 Max: 5.86
Current: 0.59
0.57
5.86
Price-to-Median-PS-Value 0.79
NYSE:LCI's Price-to-Median-PS-Value is ranked higher than
78% of the 718 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.08 vs. NYSE:LCI: 0.79 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NYSE:LCI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.48  Med: 1.23 Max: 7.92
Current: 0.79
0.48
7.92
Earnings Yield (Greenblatt) % 5.78
NYSE:LCI's Earnings Yield (Greenblatt) % is ranked higher than
73% of the 820 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. NYSE:LCI: 5.78 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NYSE:LCI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -12.9  Med: 5.6 Max: 20
Current: 5.78
-12.9
20
Forward Rate of Return (Yacktman) % 83.80
NYSE:LCI's Forward Rate of Return (Yacktman) % is ranked higher than
98% of the 381 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.46 vs. NYSE:LCI: 83.80 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
NYSE:LCI' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -11.5  Med: 4.35 Max: 129.6
Current: 83.8
-11.5
129.6

More Statistics

Revenue (TTM) (Mil) $663.11
EPS (TTM) $ -0.08
Beta2.14
Short Percentage of Float53.35%
52-Week Range $16.75 - 39.99
Shares Outstanding (Mil)37.23

Analyst Estimate

Jun17 Jun18 Jun19 Jun20
Revenue (Mil $) 660 642 643 650
EPS ($) 3.25 2.75 2.82 2.92
EPS without NRI ($) 3.25 2.75 2.82 2.92
EPS Growth Rate
(Future 3Y To 5Y Estimate)
4.00%
Dividends per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}